213 related articles for article (PubMed ID: 7864623)
1. Doxorubicin reduces the iron(III) complexes of the hydrolysis products of the antioxidant cardioprotective agent dexrazoxane (ICRF-187) and produces hydroxyl radicals.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 316(2):680-8. PubMed ID: 7864623
[TBL] [Abstract][Full Text] [Related]
2. Ferrous ion strongly promotes the ring opening of the hydrolysis intermediates of the antioxidant cardioprotective agent dexrazoxane (ICRF-187).
Buss JL; Hasinoff BB
Arch Biochem Biophys; 1995 Feb; 317(1):121-7. PubMed ID: 7872773
[TBL] [Abstract][Full Text] [Related]
3. Production of hydroxyl radical by iron(III)-anthraquinone complexes through self-reduction and through reductive activation by the xanthine oxidase/hypoxanthine system.
Malisza KL; Hasinoff BB
Arch Biochem Biophys; 1995 Aug; 321(1):51-60. PubMed ID: 7639535
[TBL] [Abstract][Full Text] [Related]
4. NADPH-cytochrome-P450 reductase promotes hydroxyl radical production by the iron complex of ADR-925, the hydrolysis product of ICRF-187 (dexrazoxane).
Hasinoff BB
Free Radic Res; 1995 Apr; 22(4):319-25. PubMed ID: 7633562
[TBL] [Abstract][Full Text] [Related]
5. Chemistry of dexrazoxane and analogues.
Hasinoff BB
Semin Oncol; 1998 Aug; 25(4 Suppl 10):3-9. PubMed ID: 9768817
[TBL] [Abstract][Full Text] [Related]
6. The doxorubicin-cardioprotective drug dexrazoxane undergoes metabolism in the rat to its metal ion-chelating form ADR-925.
Schroeder PE; Hasinoff BB
Cancer Chemother Pharmacol; 2002 Dec; 50(6):509-13. PubMed ID: 12451479
[TBL] [Abstract][Full Text] [Related]
7. The hydrolysis product of ICRF-187 promotes iron-catalysed hydroxyl radical production via the Fenton reaction.
Thomas C; Vile GF; Winterbourn CC
Biochem Pharmacol; 1993 May; 45(10):1967-72. PubMed ID: 8390256
[TBL] [Abstract][Full Text] [Related]
8. Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat.
Schroeder PE; Hasinoff BB
Drug Metab Dispos; 2005 Sep; 33(9):1367-72. PubMed ID: 15980099
[TBL] [Abstract][Full Text] [Related]
9. Hydroxyl radical production by the iron complex of the hydrolysis product of the antioxidant cardioprotective agent ICRF-187 (dexrazoxane).
Malisza KL; Hasinoff BB
Redox Rep; 1996 Feb; 2(1):69-73. PubMed ID: 27414516
[TBL] [Abstract][Full Text] [Related]
10. The one-ring open hydrolysis product intermediates of the cardioprotective agent ICRF-187 (dexrazoxane) displace iron from iron-anthracycline complexes.
Buss JL; Hasinoff BB
Agents Actions; 1993 Sep; 40(1-2):86-95. PubMed ID: 8147274
[TBL] [Abstract][Full Text] [Related]
11. The metabolites of the cardioprotective drug dexrazoxane do not protect myocytes from doxorubicin-induced cytotoxicity.
Hasinoff BB; Schroeder PE; Patel D
Mol Pharmacol; 2003 Sep; 64(3):670-8. PubMed ID: 12920203
[TBL] [Abstract][Full Text] [Related]
12. Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood.
Schroeder PE; Wang GQ; Burczynski FJ; Hasinoff BB
Drug Metab Dispos; 2005 Jun; 33(6):719-25. PubMed ID: 15764716
[TBL] [Abstract][Full Text] [Related]
13. In vitro evidence for direct complexation of ADR-529/ICRF-187 [(+)-1,2-bis-(3,5-dioxo-piperazin-1-yl)propane] onto an existing ferric-anthracycline complex.
Sobol MM; Amiet RG; Green MD
Mol Pharmacol; 1992 Jan; 41(1):8-17. PubMed ID: 1732725
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the topoisomerase II-inactive bisdioxopiperazine ICRF-161 as a protectant against doxorubicin-induced cardiomyopathy.
Martin E; Thougaard AV; Grauslund M; Jensen PB; Bjorkling F; Hasinoff BB; Tjørnelund J; Sehested M; Jensen LH
Toxicology; 2009 Jan; 255(1-2):72-9. PubMed ID: 19010377
[TBL] [Abstract][Full Text] [Related]
15. Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide.
Schroeder PE; Jensen PB; Sehested M; Hofland KF; Langer SW; Hasinoff BB
Cancer Chemother Pharmacol; 2003 Aug; 52(2):167-74. PubMed ID: 12750840
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the protective effects against chronic doxorubicin cardiotoxicity and the rates of iron (III) displacement reactions of ICRF-187 and other bisdiketopiperazines.
Herman EH; Zhang J; Hasinoff BB; Chadwick DP; Clark JR; Ferrans VJ
Cancer Chemother Pharmacol; 1997; 40(5):400-8. PubMed ID: 9272116
[TBL] [Abstract][Full Text] [Related]
17. The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin.
Wu X; Patel D; Hasinoff BB
J Inorg Biochem; 2004 Nov; 98(11):1818-23. PubMed ID: 15522409
[TBL] [Abstract][Full Text] [Related]
18. The iron chelator Dp44mT does not protect myocytes against doxorubicin.
Hasinoff BB; Patel D
J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model.
Alderton PM; Gross J; Green MD
Cancer Res; 1992 Jan; 52(1):194-201. PubMed ID: 1727379
[TBL] [Abstract][Full Text] [Related]
20. Cytoprotective agents for anthracyclines.
Dorr RT
Semin Oncol; 1996 Aug; 23(4 Suppl 8):23-34. PubMed ID: 8783663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]